Skip to main
DVAX
DVAX logo

Dynavax Technologies (DVAX) Stock Forecast & Price Target

Dynavax Technologies (DVAX) Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 25%

Bulls say

Dynavax Technologies Corp demonstrates a positive outlook due to its effective immunogenicity and tolerability results for its vaccine candidates, notably showing favorable vaccine response rates for the shingles vaccine compared to Shingrix. The company's focus on enhancing immune response through its Toll-like Receptor Immune Modulation Platform underscores its potential for significant advancements in the vaccine market. Additionally, consistent revenue generation from its existing products, such as CpG 1018 and the HEPLISAV-B vaccine, supports the financial stability and growth prospects of the company.

Bears say

Dynavax Technologies faces significant risks in the efficacy and safety of its product candidates in clinical development, which could hinder their approval and commercialization prospects. The company also encounters challenges related to effective commercialization due to competitive market conditions, internal issues, and potential litigation risks. Additionally, Dynavax’s ability to successfully partner its candidates may be compromised by unfavorable terms, further jeopardizing its commercial launch success and overall financial outlook.

Dynavax Technologies (DVAX) has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 25% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dynavax Technologies (DVAX) Forecast

Analysts have given Dynavax Technologies (DVAX) a Hold based on their latest research and market trends.

According to 4 analysts, Dynavax Technologies (DVAX) has a Hold consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dynavax Technologies (DVAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.